Pelvic floor muscle group therapy for the treatment of urinary incontinence during pregnancy and post-partum: a randomized controlled trial

HEIDI F.A. MOOSSDORFF-STEINHAUSER1, BARY C.M. BERGHMANS2, MARC E.A. SPAANDERMAN3, ESTHER M.J. BOLS1

1Department of Epidemiology, Medicine and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht University Faculty of Health, The Netherlands
2Maastricht University Medical Centre (MUMC+), Pelvic Care Center, CAPHRI, Maastricht, The Netherlands
3Department of Obstetrics and Gynaecology, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands

ABSTRACT

Objective: Pelvic Floor Muscle Group Therapy (PFMGT) is an effective treatment option in the general population. However, the effect of therapy during pregnancy and shortly thereafter is unclear. Therefore, this study investigates the effect of PFMGT in peri-partum women with UI compared to care-as-usual.

Materials and Methods: Two randomized controlled trials: study 1: pregnant women and study 2: 6 weeks post-partum women, were performed. The primary outcome was UI severity based on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short form (ICIQ-UI SF). Secondary outcomes were the Global Impression of Severity (GPE) measuring patient’s self-reported improvement and the Incontinence Impact Questionnaire-7 (IIQ-7), measuring UI impact. Descriptive and univariate analysis were reported and the non-parametric Mann-Whitney U test was used to compare differences between groups.

Results: Inclusion numbers could not be met, and therefore all women received individual Pelvic floor muscles training (PFMT). Study 1 showed no significant results regarding the prevalence of UI (ICIQ-UI SF), GPE and IIQ-7 at any measurement moment. As compared to baseline, study 2 showed a significant improvement for prevalence of UI and impact of UI at 4 months post-partum, however there was no significant difference between groups at other measurement moments. Significant subjective improvement was seen at 4th and 9th months post-partum, in favor of the PFMT group (p=0.02).

Conclusion: PFMT, started after childbirth, demonstrated improved UI and quality of life with a lower number of complaints at the 4 months post-partum assessment. However, the full potential of effectiveness of PFMT could not be established due to insufficient inclusions.

Keywords: Pelvic floor muscle group therapy; physical therapy; post-partum; pregnancy; pre-partum; urinary incontinence

Address for Correspondence: Heidi Moossdorff Steinhauer, Department of Epidemiology, Medicine and Life Sciences, Care and Public Health Research Institute (CAPHRI), Maastricht University Faculty of Health, Netherlands
E-mail: heidi.moossdorff@maastrichtuniversity.nl ORCID ID: orcid.org/0000-0002-9651-1731
Received: 23 February 2021 Accepted: 19 March 2021
©Copyright 2021 by the International Society for Pelviperineology / Pelviperineology published by Galenos Publishing House.
INTRODUCTION

Urinary incontinence (UI) is the complaint of involuntary loss of urine. The reported overall prevalence of UI varies between 25 and 46.4%. Stress urinary incontinence (SUI), the complaint of involuntary loss of urine on effort or physical exertion or on sneezing or coughing, is the most prevalent type among peripartum women. During pregnancy prevalence of UI is reported between 9 and 75%, and post-partum between 10 and 63%. UI reduces quality of life (QoL) but nonetheless, many women tend to accept their problems because they are embarrassed, think it is normal and will diminish by itself.

The development of UI peri-partum might be due to several reasons, including childbirth or physiological weight gain resulting in an increase of intra-abdominal pressure transmitted to the bladder and bladder neck, leading to urethral mobility and pelvic floor muscles (PFM) activity problems. The PFMs of women with UI during pregnancy are weaker and thinner.

PFM training (PFMT) aims to improve the supportive system and is a first-line treatment option for UI. As the costs for healthcare are rising, it is important to provide cost-effective therapies. PFMT can be provided as individual, but also as group therapy (PFMGT). PFMGT appeared to be equally effective in the treatment of UI in women in the general or older population. A recent Cochrane systematic review concluded that it is uncertain whether PFMT is an effective treatment option for women with UI during pregnancy and post-partum. Also, information on cost-effectiveness of PFMT and long-term effects is lacking.

Therefore, the primary aim of this study was to investigate whether a structured assessment and treatment program of intensive, supervised PFMTGT, including a home maintenance program, reduces 18 months post-partum UI severity (frequency, amount, and impact) compared to care-as usual (CAU) in adult pregnant (study 1) and post-partum women with SUI (study 2). The secondary aim was to investigate whether PFMTGT is cost-effective compared to CAU.

MATERIALS AND METHODS

Study design

In two randomized controlled multicenter trials, PFMT (intervention group) was compared to CAU (control group). The two studies were registered as one trial in The Netherlands National Trial Register (NTR5971). The Medical Ethics Committee (METC) of the Maastricht University Medical Center (MUMC+) has approved study 1 (METC162038) and study 2 (METC162051). The ethics boards of the participating four hospitals, Zuyderland Medical Center (two locations), Laurentius hospital and Maxima Medical Center, approved the trial, indicating also coverage for 13 local midwifery practices. The study protocol was published previously.

Participants

The women were recruited in the southern part of The Netherlands between December 1st 2017 and August 1st 2019 by midwives and physicians (case managers). Women were included if they met amongst others the following criteria: (1) ≥18 years, (2) UI (stress or mixed with predominant SUI factor, according to Haylen et al.), and (3) a score of >3 on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF). Exclusion criteria included: (1) UI prior to first pregnancy, still existing during pregnancy, (2) high-risk pregnancy, resulting in a contra-indication for performing intensive PFMT (e.g., placenta praevia, vaginal blood loss, preterm uterine contractions), (3) suffering from significant exercise limitations or co-morbidities (physical or psychological) that would restrain a woman from participation in the group therapy. A full description of inclusion and exclusion criteria is published elsewhere.

Randomization and blinding

During a regular planned consultation with their case manager, women meeting the eligibility criteria and interested to participate, received a short vaginal examination to check the ability to contract the PFMs. The candidate participant received an email with a link to the electronic baseline questionnaire after signing the informed consent. Once the questionnaires were completed, blocked randomisation was done by a computer-generated sequence in a 1:1 ratio on patient and location level. Allocation in blocks of four was concealed and done using a central computer. Participants in the intervention group, who could not contract their PFMs correctly, were referred to a specialized (pelvic) physical therapist (PT) for individual instruction before joining PFMTGT (Figure 1).

The participants, specialized PT and coordinating researcher could not be blinded. However, once the participant completed the questionnaires, they were blocked from making alterations. Before the statistical analyses all participants were appointed a new study number for which the coordinating researcher was blinded. Therefore, analyses were done blinded for treatment allocation.

Intervention

The intervention was provided by one specialized PT in every region. In Netherlands, pelvic PT is a specialisation within the field of physical therapy and has its own registration in order to guarantee quality. The specialized PT’s were instructed on the PFMTGT protocol which consisted of eight once weekly PFMTGT sessions of 60 minutes each. Pregnant and post-partum women...
could participate as soon as they were randomized in the same intervention group, with a maximum of four per group. The intervention included instructions on pelvic floor anatomy and how to contract, relax and train the PFMs correctly in combination with general physical exercises with a strong focus on self-management. The PFMGT protocol has been published previously.21 The women in the intervention group received a mApp (iPelvis),25 which is an application with individualized pelvic PT exercises to reinforce adherence to and compliance with a home maintenance program.

Figure 1. Flowchart study 1

T: measurement, wks: weeks, mos: months, N: number, PFMGT: pelvic floor muscle group therapy
Care-as-usual
Participants in the CAU group received regular advice from their case managers and were free to participate in any pregnancy-related course or visit a health care professional for their UI.

Measurements
Besides the measurement of the baseline characteristics in both studies the women were asked to fill in the questionnaires multiple times (Figure 1 and 2).

Primary outcome measure
The primary outcome is based on the ICIQ-UI SF. This is a validated brief (four questions) measure for evaluating the frequency, severity and impact on QoL of UI.26 The total score ranges from 0 (not affected) to 21 (severely affected). The questionnaire is translated in Dutch.27 Therapy success is defined as absence of UI or change from baseline of at least three points on the ICIQ-UI SF at 18 months post-partum.28

Secondary outcome measures
The Patient Global Impression of Severity (GPE) questionnaire was used to assess the patients' self-reported improvement.29 It is a reliable scale for incontinence, consisting of one question and seven response options ranging from very much improved to very much deterioration.30,31 The validated Incontinence Impact Questionnaire-7 (IIQ-7) was used to determine the UI impact on four domains: mobility, physical functioning, emotional health and embarrassment.32 The total score ranges from 0 to 100, 0 meaning no impact and 100 extreme impact.

Sample size
The total sample size estimate for study 1 was 150, and study 2 was 90. These numbers are based on a significance level of 0.05, a power of 90%, and a 20% drop-out rate. Further justification has been described elsewhere.21

Statistical analysis
The Consolidated Standards of Reporting Trials (CONSORT) statement was followed for reporting the trial.31 Data was analysed according to the intention-to-treat principle. Descriptive and univariate analysis were reported as means and standard deviations or 95% confidence intervals. The non-parametric Mann-Whitney U test was performed to compare differences between the two groups. A p-value <0.05 is considered to be statistically significant. Data analyses are carried out using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, N.Y., USA).

RESULTS
Recruitment took place between 01.06.2017 and 01.08.2019.

Participants
In study 1, 59 women were eligible for participation, of which 24 women were randomized (intervention group=11, control group=13) (Figure 1). Four participants completed the study (Figure 1). In study 2, 116 women were eligible of which 23 were randomized (intervention group=10, control group=13), 14 participants completed the study (Figure 2). Characteristics of the participants for study 1 and 2 are shown in Table 1.

Outcomes
The results are based on individual PFMT instead of PFMGT, as groups did not fill sufficiently (therefore, from this point on the term PFMT will be used). However, the original PFMGT protocol was followed. Study 1 showed no statistically significant differences between groups at any point regarding the ICIQ-UI SF total score, GPE and IIQ-7 (Table 2), although both groups showed improvements on all outcomes post-intervention.

In study 2, the intervention group improved significantly compared to the control group (p=0.012) at four months post-partum with regard to the ICIQ-UI SF score of (p=0.012) and IIQ-7 (p=0.04). Moreover, the GPE of the intervention group improved significantly at T1 and T2 (p=0.02). T3 showed no statistically significant difference between groups (Table 2).

The mean number of days per week the participants performed PFM exercises during the eighth week PFMGT was 5.9 (median 6.0) and 5.0 (median 5.3) in study 1 and 2, respectively. Cost-effectiveness outcomes have not been calculated because both studies were underpowered.

DISCUSSION
The cost-effectiveness of PFMT, for pregnant (study 1) and post-partum women (study 2) with SUI could not be established as planned, due to the small number of included women in both studies. As a consequence of the small numbers, all women in the intervention group received individual PFMT. Therefore, the reported results should be interpreted with great caution and no conclusions regarding the original hypothesis can be made.

PFMT started during pregnancy showed no significant results regarding the effect on UI, impact, and self-perceived impression of severity of symptoms at any point. This is in line with a recent Cochrane systematic review, reporting no evidence of the treatment effect of PFMT on UI in late pregnancy.20 Most likely our findings must be explained by the fact the study is underpowered. In addition, during pregnancy the continence
Figure 2. Flowchart study 2

T: measurement, wks: weeks, mos: months, PFMGT: pelvic floor muscle group therapy
mechanism is challenged by a multitude of factors of which some are non-modifiable. Physiological weight gain, and changes in the neuromuscular function of the urethral sphincter are considered examples of non-modifiable factors. However, PFMT in the general female population is a proven effective intervention.

PFMT post-partum revealed a positive effect directly after PFMT regarding UI, impact and self-perceived impression of severity. However, this effect was not maintained at later follow-up, except for subjective improvement. Although this study focused on adherence strategies for PFMT, the effect did not last.

### Table 1. Participants’ characteristics

|                      | Study 1 n (%) | Study 2 n (%) |
|----------------------|---------------|---------------|
|                      | I (11)        | C (13)        | Total (24) | I (10) | C (13) | Total (23) |
| **Age (mean, range)**|               |               |            |        |        |            |
| Secondary            | 32.1 (24-38)  | 32.9 (23-42)  | 32.5 (23-42) | 32.3 (27-37) | 30.2 (24-37) | 31.0 (24-37) |
| Tertiary             | 4 (36.4)      | 4 (30.8)      | 8 (33.3)   | 3 (30.0) | 5 (38.5) | 8 (34.8)   |
| **Parity**           |               |               |            |        |        |            |
| 0                    | 4 (36.4)      | 4 (30.8)      | 8 (33.3)   | -      | -      | -          |
| 1                    | 7 (63.6)      | 9 (69.2)      | 16 (66.7)  | 7 (70.0) | 8 (61.5) | 15 (65.2)  |
| ≥2                   | 0 (0)         | 2 (15.4)      | 2 (4.2)    | 1 (10.0) | 1 (7.7) | 2           |
| **Missing**          | 7             | 7             | 14         |        |        |            |

n: number, I: intervention group, C: control group

### Table 2. Results ICIQ-UI SF, GPE and IIQ-7

#### Study 1

|                      | Baseline | T1 | T2 | T3 |
|----------------------|----------|----|----|----|
|                      | 12-26 weeks gestation | 34 weeks gestation | 6 weeks post-partum | 6 months post-partum |
| I (11)               | C (13)   | T (24) | I (4) | C (12) | T (16) | I (4) | C (11) | T (15) | I (3) | C (10) | T (13) |
| ICIQ-U1 SF (range 0-21) | 11.2 (2.0) (8-14) | 9.5 (3.2) (5-15) | 10.3 (2.8) (5-15) | 6.8 (2.2) (4-9) | 8.6 (3.8) (4-14) | 8.1 (3.5) (4-14) | 6.8 (2.2) (4-9) | 6.1 (3.9) (0-11) | 6.3 (3.5) (0-11) | 7.3 (1.5) (6-9) | 5.9 (3.8) (0-11) | 6.2 (3.4) (0-11) | p=0.17Ø |
| GPE (range: 1-7)     | -        | -   | -  | -   |
| IIQ-7 (range: 0-100) | 14.3 (0.57.1) | 16.8 (0.57.1) | 13.1 (0.19.0) | 15.9 (0.57.1) | 10.7 (0.28.5) | 9.9 (0.38.1) | 7.9 (0.14.3) | 4.8 (0.23.8) | p=0.40 |

#### Study 2

|                      | Baseline | 4 months post-partum | 9 months post-partum | 18 months post-partum |
|----------------------|----------|----------------------|----------------------|----------------------|
|                      | 6 weeks post-partum | T1 | T2 | T3 | T1 | T2 | T3 | T1 | T2 | T3 |
| I (10)               | C (13)   | T (23) | I (8) | C (12) | T (20) | I (5) | C (11) | T (16) | I (6) | C (8) | T (14) |
| ICIQ-U1 SF (range 0-21) | 8.3 (1.9) (5-11) | 8.6 (2.5) (6-13) | 8.5 (2.2) (5-13) | 5.3 (3.0) (0-11) | 8.7 (2.9) (5-13) | 7.2 (3.3) (0-13) | 4.2 (2.6) (1-8) | 7.5 (3.8) (0-13) | 6.4 (3.7) (0-13) | 4.3 (5.2) (5-13) | 8.4 (3.6) (1-12) | 6.6 (4.7) (0-13) | p=0.03* |
| GPE (range: 1-7)     | -        | -       | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   |
| IIQ-7 (range: 0-100) | 14.3 (0.38.1) | 19.1 (0.57.1) | 6.0 (0.19.1) | 23.0 (0.57.1) | 13.3 (0.47.6) | 20.3 (0.66.7) | 13.3 (0.47.6) | 20.3 (0.66.7) | 13.3 (0.47.6) | 20.3 (0.66.7) | 13.3 (0.47.6) | 20.3 (0.66.7) | 13.3 (0.47.6) | p=0.09 |

I: Intervention group, C: Control group; T: Total group, T1: Follow-up 1; T2: Follow-up 2; T3: Follow-up 3; T4: Follow-up 4; ICIQ-U1 SF: International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form; GPE: Global perceived effect; IIQ-7: Incontinence Impact Questionnaire-7; Ø: significant, *: significant, p= value.
We anticipated no major problems in recruiting the necessary number of participants for both studies due to a number of reasons. Firstly, the recruitment was done by case managers covering the majority of maternal care (pre- and post-partum care) in the southern part of The Netherlands, in which over 8,500 babies were born in 2019. Secondly, high prevalence rates of SUI during pregnancy and post-partum are reported in numerous studies and thirdly, other studies on PFMT peri-partum in northern Europe reported high inclusion and participation rates. Nonetheless, recruitment proved to be problematic.

In order to improve the number of inclusions several alterations to the eligibility criteria of the study were proposed and granted. The changes were: 1. inclusion of all women regardless of parity instead of only primigravid and primiparous women. 2. extending the inclusion period from 12 to 20 weeks up to 26 weeks of gestation. Other strategies to improve the inclusion rate were: regular presentations in the participating hospitals, visits to midwifery practices, attending clinics and regular phone conversations with midwives and research assistants of the hospitals. Also, a monthly newsletter informing the healthcare professionals was sent.

Several factors might explain the disappointing inclusion numbers, which might also be useful for other researchers in the field to plan their studies or optimize their recruitment strategies. Firstly, our studies were so called ‘efficiency studies’ in which two different treatments are compared with regard to effect and financial costs, with the objective to discourage use of inefficient interventions. Due to this design, participants were only allowed to be included by a case manager like a midwife or obstetrician, which might have influenced the disappointing inclusion numbers. In the study of Mørkved et al. on the effect of PFMT to prevent UI during pregnancy, all women were asked to participate through a letter which they received in combination with the invitation for their standard appointment with their case manager. Secondly, a standard question on UI is lacking in electronic patient following systems in The Netherlands for case managers reporting peri-partum care. This digital reminder to ask for UI might have influenced the inclusion numbers. Thirdly, case managers involved in these studies mentioned their lack of attention as a major barrier to recruit participants together with lack of time and a difficult to implement protocol in usual clinical practice. These are well known barriers in clinical research. Moreover, the case managers also mentioned that the standard internal assessment of the PFM in the protocol was a barrier due to lack of time. The number of drop-outs in study 1, once randomized, and in the initial inclusion phase in study 2, can be explained by known barriers for patient participation like inconvenience due to extra appointments, travel problems, costs and a preference for a specific study arm.

Fourth, the sample size calculation for both studies was based on reported high UI prevalence numbers. However, the experienced bother was not taken into account. This might have resulted in an overestimation of the crude prevalence of UI, because level of experienced bother is associated with help-seeking behavior.

Our result regarding PFMT post-partum may justify and therefore support the recommendation of Woodley et al. for the development of a new RCT on this subject. However, it is advisable to recruit women through for instance (social) media because questions on UI are not standardly asked by health care professionals.

Strengths of this study include that the intervention offered in both studies is protocol- and evidence based and the ability to contract the PFM is checked. Women who did not know how to contract the PFM received an individual session by a specialized PT in order to learn how to contract and relax, before joining PFMT; in addition to the protocol has a strong emphasis on adherence with the use of a mApp. A mApp has shown to have a beneficial effect on adherence. The original design includes a long follow-up period and cost-effectiveness calculation.

In conclusion, PFMT, started post-partum, demonstrated statistically significant improvements in UI and QoL with a lower number of complaints at the 4 months post-partum assessment. However, the full potential of effectiveness of PFMGT could not be established due to insufficient inclusions, the latter most likely due to accepted bother from UI rather than the presence of UI itself.

Acknowledgements

We would like to thank all case managers for recruiting participants and all pelvic physical therapists for the treatment of participants. We also thank Mrs. Julia H. Herbert for checking the English language.

Contributions

Surgical and Medical Practices: H.F.A.M., E.M.J.B., B.C.M.B., Concept: B.C.M.B., M.E.A.S., Design: H.F.A.M., E.M.J.B., M.E.A.S., B.C.M.B., Data Collection or Processing: H.F.A.M., E.M.J.B., Analysis or Interpretation: H.F.A.M., E.M.J.B., Literature Search: H.F.A.M., Writing: H.F.A.M., E.M.J.B., B.C.M.B., M.E.A.S.

Ethics

Ethics Committee Approval: This study was approved by Maastricht University (no: METC162038).

Informed Consent: Informed consent was obtained.
D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 2019; 38: 433-77.

Schreiber Pedersen L, Lose G, Høybye MT, Elsner S, Waldmann A, Rudnicki M. Prevalence of urinary incontinence among women and analysis of potential risk factors in Germany and Denmark. Acta Obstet Gynecol Scand 2017; 96: 939-48.

Hannestad YS, Rortveit G, Sandvik H, Hunskaar S; Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. J Clin Epidemiol 2000; 53: 1150-7.

Botlero R, Davis SR, Urquhart DM, Shortreed S, Bell RJ. Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas 2009; 62: 134-9.

Højberg KE, Salvig JD, Winsløw NA, Lose G, Secher NJ. Urinary incontinence: prevalence and risk factors at 16 weeks of gestation. Br J Obstet Gynaecol 1999; 106: 842-50.

Nigam A, Ahmad A, Gaur D, Elahi A, Batra S. Prevalence and risk factors for urinary incontinence in pregnant women in late third trimester. IJRCOG 2016; 5: 2187-91.

Rikard-Bell J, Iyer J, Rane A. Perineal outcome and the risk of pelvic floor dysfunction: a cohort study of primiparous women. Aust N Z J Obstet Gynaecol 2014; 54: 371-6.

Moossdorff-Steinhauser HFA, Berghmans BCM, Spaanderman MEA, Bols EMJ. Urinary incontinence during pregnancy: prevalence, experience of bother, beliefs, and help-seeking behavior. Int Urogynecol J 2021; 32: 695-701.

Buurman MB, Lagro-Janssen AL. Women’s perception of postpartum pelvic floor dysfunction and their help-seeking behaviour: a qualitative interview study. Scand J Caring Sci 2013; 27: 406-13.

Mason L, Glenn S, Walton I, Hughes C. Women’s reluctance to seek help for stress incontinence during pregnancy and following childbirth. Midwifery 2001; 17: 212-21.

Swenson CW, Kolenic GE, Trowbridge ER, et al. Obesity and stress urinary incontinence in women: compromised continence mechanism or excess bladder pressure during cough? Int Urogynecol J 2017; 28: 1377-85.

DeLancey JO, Kearney R, Chou Q, Speights S, Binno S. The appearance of levator ani muscle abnormalities in magnetic resonance images after vaginal delivery. Obstet Gynecol 2003; 101: 46-53.

MacLennan AH, Taylor AW, Wilson DH, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG 2000; 107: 1460-70.

Markved S, Salvesen KA, Børk E, Eik-Nes S. Pelvic floor muscle strength and thickness in continent and incontinent nulliparous pregnant women. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15: 384-9.

NICE. Urinary incontinence in women: management (cg 171). 2013; https://www.nhsggc.org.uk/media/251043/nice-guideline-urinary-incontinence-in-women-management.pdf (Accessed 2 May 2020).

Kobashi K, Albo M, Dmochowski R, et al. Surgical Treatment of Female Stress Urinary Incontinence: AUA/SUFU Guideline. The Journal of Urology 2017; 198: 875-83.

CBS Statline. Geboorte; kerncijfers vruchtbaarheid, leeftijd moeder, regio. 2020 29 June 2020. https://opendata.cbs.nl/statline/?themaNr=82388#/CBS/nl/dataset/37201/table?ts=1599385813955

Paiva LL, Ferla L, Darski C, Catarino BM, Ramos JG. Pelvic floor muscle training in groups versus individual or home treatment of women with urinary incontinence: systematic review and meta-analysis. Int Urogynecol J 2017; 28: 351-9.

Dumoulin C, Morin M, Danieli C, et al. Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial. JAMA Intern Med 2020; 180: 1284-93.

Woodley SJ, Lawrenson P, Boyle R, et al. Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev 2020; 5: CD007471.

Moossdorff-Steinhauser HFA, Bols EMJ, Spaanderman MEA, et al. Long-term effects of motherfit group therapy in pre-(MOTHERFIT1) and post-partum women (MOTHERFIT2) with stress urinary incontinence compared to care-as-usual: study protocol of two multi-centred, randomised controlled trials. Trials 2019; 20: 237.

Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21: 5-26.

Timmermans L, Falez F, Mélot C, Wespes E. Validation of use of the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF) for impairment rating: a transversal retrospective study of 120 patients. Neurourol Urodyn 2013; 32: 974-9.

Westerik-Verschuuren L, Moossdorff-Steinhauser H. Beroepsprofiel bekkenfysiotherapeut. KNGF Augustus 2014; 1-59.
25. Latorre GFS, de Fraga R, Seleme MR, Mueller CV, Berghmans B. An ideal e-health system for pelvic floor muscle training adherence: Systematic review. Neurourol Urodyn 2019; 38: 63-80.

26. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23: 322-30.

27. Grzybowska ME, Wydra D. 24/7 usage of continence pads and quality of life impairment in women with urinary incontinence. Int J Clin Pract 2019; 73: e13267.

28. Nyström E, Sjöström M, Stenlund H, Samuelsson E. ICIQ symptom and quality of life instruments measure clinically relevant improvements in women with stress urinary incontinence. Neurourol Urodyn 2015; 34: 747-51.

29. Hudak PL, Wright JG. The characteristics of patient satisfaction measures. Spine (Phila Pa 1976) 2000; 25: 3167-77.

30. Kamper SJ, Ostelo RW, Knol DL, Maher CG, de Vet HC, Hancock MJ. Global Perceived Effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. J Clin Epidemiol 2010; 63: 760-6.e1.

31. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003; 189: 98-101.

32. Utomo E, Korfage IJ, Wildhagen MF, Steensma AB, Bangma CH, Blok BF. Validation of the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) in a Dutch population. Neurourol Urodyn 2015; 34: 24-31.

33. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med 2017; 167: 40-7.

34. Weidner AC, South MM, Sanders DB, Stinnett SS. Change in urethral sphincter neuromuscular function during pregnancy persists after delivery. Am J Obstet Gynecol 2009; 201: 529.e1-6.

35. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2018; 10: CD005654.

36. Mørkved S, Bø K, Schei B, Salvesen KA. Pelvic floor muscle training during pregnancy to prevent urinary incontinence: a single-blind randomized controlled trial. Obstet Gynecol 2003; 101: 313-9.

37. ZonMw. Research and results/efficiency studies. https://www.zonmw.nl/en/research-and-results/efficiency-studies/#:~:text=Efficiency%20Studies%20provide%20the%20evidence,%2C%20researchers%2C%20practitioners%20and%20policymakers (Accessed 20 October, 2020).

38. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999; 52: 1143-56.

39. Isaksson E, Wester P, Laska AC, Näsman P, Lundström E. Identifying important barriers to recruitment of patients in randomised clinical studies using a questionnaire for study personnel. Trials 2019; 20: 618.

40. Monz B, Chartier-Kastler E, Hampel C, et al. Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE. Eur Urol 2007; 51: 1073-81.

41. National Institute for health and care excellence (NICE). Antenatal care for uncomplicated pregnancies (CG62). 2008; https://www.nice.org.uk/guidance/cg62/resources/antenatal-care-for-uncomplicated-pregnancies-pdf-975564597445 (Accessed 8 February, 2021).

42. Bernard S, Boucher S, McLean L, Moffet H. Mobile technologies for the conservative self-management of urinary incontinence: a systematic scoping review. Int Urogynecol J 2020; 31: 1163-74.

43. Araujo CC, Marques AA, Juliato CRT. The adherence of home pelvic floor muscles training using a mobile device application for women with urinary incontinence: a randomized controlled trial. Female Pelvic Med Reconstr Surg 2020; 26: 697-703.